SOHO 2021 | Updates on BiTEs for B-ALL
Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, gives an overview of the latest findings from research into the therapeutic use of bispecific T-cell engagers (BiTEs) for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), in particular blinatumomab. Dr Rau comments on trials exploring blinatumomab both in the adult and pediatric settings, in particular highlighting the AA1331 trial (NCT02101853). Dr Rau also talks on a trial exploring the use of nivolumab in combination with blinatumomab to enhance blinatumomab’s efficacy, and comments on the challenges of treating B-ALL linked to Down Syndrome. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.
